Insmed (NASDAQ:INSM) Price Target Increased to $75.00 by Analysts at Evercore ISI

Insmed (NASDAQ:INSM – Free Report) had its price target boosted by Evercore ISI from $42.00 to $75.00 in a research report released on Friday, Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on the stock. Stifel Nicolaus raised […]

Leave a Reply

Your email address will not be published.

Previous post Analyzing Emergent BioSolutions (NYSE:EBS) and ABIVAX Société Anonyme (NASDAQ:ABVX)
Next post SM Energy (NYSE:SM) versus Barnwell Industries (NYSE:BRN) Head-To-Head Survey